CL2011001714A1 - Compuestos derivados de bencenosulfonamidas, bloqueadores de canales de calcio; composicion farmaceutica que los comprende; uso en el tratamiento del dolor y enfermedades del snc. - Google Patents
Compuestos derivados de bencenosulfonamidas, bloqueadores de canales de calcio; composicion farmaceutica que los comprende; uso en el tratamiento del dolor y enfermedades del snc.Info
- Publication number
- CL2011001714A1 CL2011001714A1 CL2011001714A CL2011001714A CL2011001714A1 CL 2011001714 A1 CL2011001714 A1 CL 2011001714A1 CL 2011001714 A CL2011001714 A CL 2011001714A CL 2011001714 A CL2011001714 A CL 2011001714A CL 2011001714 A1 CL2011001714 A1 CL 2011001714A1
- Authority
- CL
- Chile
- Prior art keywords
- pain
- benzenesulfonamides
- pharmaceutical composition
- calcium channel
- channel blockers
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 5
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract 2
- 150000008331 benzenesulfonamides Chemical class 0.000 title abstract 2
- 239000000480 calcium channel blocker Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14489909P | 2009-01-15 | 2009-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001714A1 true CL2011001714A1 (es) | 2011-11-11 |
Family
ID=41796157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001714A CL2011001714A1 (es) | 2009-01-15 | 2011-07-14 | Compuestos derivados de bencenosulfonamidas, bloqueadores de canales de calcio; composicion farmaceutica que los comprende; uso en el tratamiento del dolor y enfermedades del snc. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8101614B2 (enExample) |
| EP (1) | EP2382191B1 (enExample) |
| JP (1) | JP5619773B2 (enExample) |
| KR (1) | KR20110110299A (enExample) |
| CN (1) | CN102282131B (enExample) |
| AR (1) | AR077440A1 (enExample) |
| AU (1) | AU2010204753A1 (enExample) |
| BR (1) | BRPI1005675A2 (enExample) |
| CA (1) | CA2747752A1 (enExample) |
| CL (1) | CL2011001714A1 (enExample) |
| CO (1) | CO6400194A2 (enExample) |
| DO (1) | DOP2011000217A (enExample) |
| ES (1) | ES2527467T3 (enExample) |
| IL (1) | IL213500A0 (enExample) |
| MX (1) | MX337190B (enExample) |
| PE (1) | PE20120126A1 (enExample) |
| RU (1) | RU2011134052A (enExample) |
| SG (1) | SG172308A1 (enExample) |
| TW (1) | TW201028421A (enExample) |
| UY (1) | UY32384A (enExample) |
| WO (1) | WO2010083264A1 (enExample) |
| ZA (1) | ZA201104715B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352492B (zh) | 2008-04-24 | 2017-12-05 | Msd K.K.公司 | 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂 |
| TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| AU2012308243B2 (en) * | 2011-09-15 | 2017-09-14 | Taipei Medical University | Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury |
| UY34349A (es) | 2011-09-29 | 2013-04-05 | Abb Vie Inc | OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO |
| WO2013049164A1 (en) | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| US20130178477A1 (en) * | 2012-01-05 | 2013-07-11 | Abbvie Inc. | Methods of treating diabetic neuropathy using benzenesulfonamides |
| AU2013359533A1 (en) * | 2012-12-12 | 2015-05-28 | Abbvie, Inc. | Diazepine derivatives useful as calcium channel blockers in the treatment of pain |
| RU2727516C2 (ru) | 2013-09-10 | 2020-07-22 | Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Терапевтические средства, нацеленные на укороченные белки аденоматозного полипоза толстого кишечника (арс) |
| WO2015051336A1 (en) | 2013-10-03 | 2015-04-09 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
| US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
| EP3364993B1 (en) | 2015-10-22 | 2022-11-09 | Cavion, Inc. | Methods for treating angelman syndrome |
| CN110545806A (zh) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| EP3615521A4 (en) | 2017-04-26 | 2021-02-17 | Cavion, Inc. | METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS |
| AU2019207491A1 (en) | 2018-01-10 | 2020-07-30 | Cura Therapeutics, Llc | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
| US11858910B2 (en) | 2018-08-24 | 2024-01-02 | Sunshine Lake Pharma Co., Ltd. | Pyridinylmethylenepiperidine derivatives and uses thereof |
| JP7480131B2 (ja) | 2018-10-03 | 2024-05-09 | カビオン・インコーポレイテッド | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
| US20200131156A1 (en) * | 2018-10-30 | 2020-04-30 | H. Lundbeck A/S | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS |
| WO2021007478A1 (en) * | 2019-07-11 | 2021-01-14 | Cura Therapeutics, Llc | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
| WO2021007487A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
| CN117229257B (zh) * | 2022-06-06 | 2026-01-30 | 中国药科大学 | 间氨磺酰苯甲酰胺类化合物及制法、药物组合物和应用 |
| WO2025255502A1 (en) | 2024-06-07 | 2025-12-11 | Cavion, Inc. | PYRIDYL AMIDE Cav3 CHANNEL MODULATORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE269848T1 (de) | 1999-04-07 | 2004-07-15 | Univ Virginia | Calciumkanalblocker als antikrebsmittel |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| US7223754B2 (en) | 2003-03-10 | 2007-05-29 | Dynogen Pharmaceuticals, Inc. | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders |
| DE602004027171D1 (de) * | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| JP2006523707A (ja) * | 2003-04-15 | 2006-10-19 | アストラゼネカ アクツィエボラーグ | 治療化合物 |
| WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| EP2074105A4 (en) * | 2006-10-13 | 2010-10-06 | Neuromed Pharmaceuticals Ltd | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM INHIBITORS |
| KR20100033981A (ko) * | 2007-06-03 | 2010-03-31 | 벤더르빌트 유니버시티 | 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법 |
| CN104352492B (zh) | 2008-04-24 | 2017-12-05 | Msd K.K.公司 | 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂 |
| TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
-
2009
- 2009-12-31 TW TW098146447A patent/TW201028421A/zh unknown
-
2010
- 2010-01-14 MX MX2011007496A patent/MX337190B/es active IP Right Grant
- 2010-01-14 BR BRPI1005675A patent/BRPI1005675A2/pt not_active IP Right Cessation
- 2010-01-14 CN CN201080004675.3A patent/CN102282131B/zh not_active Expired - Fee Related
- 2010-01-14 CA CA2747752A patent/CA2747752A1/en active Pending
- 2010-01-14 US US12/687,465 patent/US8101614B2/en not_active Expired - Fee Related
- 2010-01-14 SG SG2011045564A patent/SG172308A1/en unknown
- 2010-01-14 EP EP10701070.4A patent/EP2382191B1/en active Active
- 2010-01-14 ES ES10701070.4T patent/ES2527467T3/es active Active
- 2010-01-14 PE PE2011001348A patent/PE20120126A1/es not_active Application Discontinuation
- 2010-01-14 JP JP2011546319A patent/JP5619773B2/ja not_active Expired - Fee Related
- 2010-01-14 KR KR1020117018567A patent/KR20110110299A/ko not_active Withdrawn
- 2010-01-14 WO PCT/US2010/020964 patent/WO2010083264A1/en not_active Ceased
- 2010-01-14 RU RU2011134052/04A patent/RU2011134052A/ru not_active Application Discontinuation
- 2010-01-14 AU AU2010204753A patent/AU2010204753A1/en not_active Abandoned
- 2010-01-15 UY UY0001032384A patent/UY32384A/es not_active Application Discontinuation
- 2010-01-15 AR ARP100100091A patent/AR077440A1/es not_active Application Discontinuation
-
2011
- 2011-06-12 IL IL213500A patent/IL213500A0/en unknown
- 2011-06-24 ZA ZA2011/04715A patent/ZA201104715B/en unknown
- 2011-07-07 DO DO2011000217A patent/DOP2011000217A/es unknown
- 2011-07-14 CL CL2011001714A patent/CL2011001714A1/es unknown
- 2011-08-02 CO CO11097206A patent/CO6400194A2/es not_active Application Discontinuation
- 2011-12-12 US US13/323,029 patent/US8404719B2/en active Active
-
2013
- 2013-02-04 US US13/758,615 patent/US8741899B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2527467T3 (es) | 2015-01-26 |
| UY32384A (es) | 2010-08-31 |
| JP5619773B2 (ja) | 2014-11-05 |
| US8741899B2 (en) | 2014-06-03 |
| AU2010204753A1 (en) | 2011-08-11 |
| BRPI1005675A2 (pt) | 2017-06-13 |
| JP2012515209A (ja) | 2012-07-05 |
| WO2010083264A1 (en) | 2010-07-22 |
| EP2382191A1 (en) | 2011-11-02 |
| MX337190B (es) | 2016-02-16 |
| TW201028421A (en) | 2010-08-01 |
| US20100197693A1 (en) | 2010-08-05 |
| US8101614B2 (en) | 2012-01-24 |
| PE20120126A1 (es) | 2012-03-18 |
| MX2011007496A (es) | 2011-08-04 |
| US20120083499A1 (en) | 2012-04-05 |
| SG172308A1 (en) | 2011-07-28 |
| RU2011134052A (ru) | 2013-02-20 |
| US20130210827A1 (en) | 2013-08-15 |
| KR20110110299A (ko) | 2011-10-06 |
| ZA201104715B (en) | 2014-01-29 |
| DOP2011000217A (es) | 2011-07-31 |
| CA2747752A1 (en) | 2010-07-22 |
| EP2382191B1 (en) | 2014-11-12 |
| CO6400194A2 (es) | 2012-03-15 |
| US8404719B2 (en) | 2013-03-26 |
| CN102282131A (zh) | 2011-12-14 |
| CN102282131B (zh) | 2015-08-26 |
| AR077440A1 (es) | 2011-08-31 |
| IL213500A0 (en) | 2011-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011001176A1 (es) | Compuestos octahidrociclopenta[c]pirrol-4-amina sustituidos, bloqueadores de los canales de calcio; composicion farmaceutica; y su uso en el tratamiento del dolor, tal como dolor agudo, dolor cronico y dolor neuropatico y para trastornos del sistema nervioso central tales como accidente cerebrovascular y epilepsia, entre otros. | |
| UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CL2011000488A1 (es) | Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus. | |
| CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| CL2011001923A1 (es) | Compuestos agonistas y antagonistas del receptor s1p5; y uso de los compuestos en la preparacion de medicamentos útiles para el tratamiento de enfermedades mediadas por el refceptor s1p, tales como enfermedades neurodedenerativas. | |
| ECSP12011908A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO | |
| GT201500294A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| MX377877B (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
| CL2008002246A1 (es) | Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion. | |
| CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
| CL2011000144A1 (es) | Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros. | |
| CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
| UY34654A (es) | Inhibidores de la beta-secretasa | |
| CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
| CL2016002615A1 (es) | Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos. | |
| UY31340A1 (es) | Moduladores tieno- y furo-pirimidina del receptor de histamina h4 | |
| ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| CL2011002160A1 (es) | Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. | |
| EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина | |
| CL2015000460A1 (es) | Compuestos derivados de 2-il-pirrol carboxamidas fluorometilo sustituidas, bloqueadores de canales de calcio activados por voltaje; composicion farmaceutica; uso para el tratamiento y/o profilaxis de trastornos relacionados con dolor, apoplejia, trastorno de personalidad, epilepsia, esquizofrenia y trastornos neurodegenerativos. | |
| MX2017015292A (es) | Composicion para tratar lesiones cerebrales. |